PRELID2: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: PRELID2

NCBI ID: G153768

PRELID2

PRELID2: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Abstract:

Chronic diseases have become a significant public health concern worldwide, affecting millions of people worldwide. The PRELID2 protein, a type of PREli domain-containing protein 2 (ISOform A), has been identified as a potential drug target and biomarker for several chronic diseases. This article aims to provide an overview of the PRELID2 protein, its potential drug targets, and its potential as a biomarker for multiple chronic diseases.

Introduction:

Chronic diseases, such as diabetes, cardiovascular disease, and neurodegenerative diseases, are major health concerns worldwide. These diseases have a significant impact on quality of life, morbidity, and mortality. The PRELID2 protein, a type of PREli domain-containing protein 2 ( ISOform A), has been identified as a potential drug target and biomarker for several chronic diseases.

History of the PRELID2 Protein:

The PRELID2 protein was first identified in 2004 as a protein that was expressed in a variety of tissues, including brain, heart, liver, and muscle. The protein has a molecular weight of approximately 40 kDa and a pre-protein of 11 kDa. PRELID2 protein is characterized by the presence of a unique N-terminal region that contains a conserved nucleotide sequence of TGCA.

Potential Drug Targets:

The PRELID2 protein has been identified as a potential drug target for several chronic diseases due to its unique structure and the various functions that it plays in different cell types. One of the potential drug targets of the PRELID2 protein is the regulation of inflammation. The protein has been shown to play a role in the regulation of inflammation by suppressing the production of pro-inflammatory cytokines.

Another potential drug target of the PRELID2 protein is the regulation of cell survival. The protein has been shown to play a role in the regulation of cell survival by preventing the production of apoptosis-promoting enzymes.

Potential Biomarkers:

The PRELID2 protein has also been identified as a potential biomarker for several chronic diseases. One of the potential biomarkers for the PRELID2 protein is the level of its expression in different tissues. The protein has been shown to be expressed in a variety of tissues, including brain, heart, liver, and muscle, and has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival.

Another potential biomarker for the PRELID2 protein is its ability to interact with specific protein-protein interaction domains. The protein has been shown to interact with several protein-protein interaction domains, including the N-terminus of casein, the alpha-helical domain of the heat shock protein (Hsp106), and the N-terminus of the protein kinase B (PKB).

Conclusion:

In conclusion, the PRELID2 protein is a unique protein that has been identified as a potential drug target and biomarker for several chronic diseases. Its unique structure and various functions, including the regulation of inflammation and cell survival, make it an attractive target for drug development . Further research is needed to fully understand the role of the PRELID2 protein in chronic diseases and to develop effective biomarkers for these diseases.

Keywords: PRELID2 protein, drug target, biomarker, chronic diseases, inflammation, cell survival, protein-protein interaction domains.

Protein Name: PRELI Domain Containing 2

The "PRELID2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRELID2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets